Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GABBR2 | O75899 | 3/20 | 0.35 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | BLM | P54132 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4100201 | 0.87 | ALDH1A1 (0.48) | ALDH1A1GABBR2GABBR1CYP1A2TSHR | |
| SCHEMBL4760429 | 0.76 | LMNA (0.54) | ALDH1A1GABBR2GABBR1CYP1A2TSHR | |
| SCHEMBL4717100 | 0.74 | LMNA (0.46) | ALDH1A1GABBR2GABBR1CYP1A2TSHR | |
| SCHEMBL8459566 | 0.72 | ALDH1A1 (0.38) | ALDH1A1GABBR2GABBR1CYP1A2TSHR | |
| SCHEMBL6051946 | 0.71 | ALDH1A1 (0.41) | ALDH1A1GABBR2GABBR1CYP1A2TSHR | |
| SCHEMBL23104805 | 0.70 | — | — | |
| SCHEMBL249493 | 0.69 | CA4 (0.46) | TSHRTHPOBLMCA4 | |
| SCHEMBL27763994 | 0.69 | CA4 (0.33) | TSHRTHPOCA4 | |
| SCHEMBL20481779 | 0.67 | CA4 (0.43) | TSHRTHPOBLMCA4 | |
| SCHEMBL4311069 | 0.67 | CA4 (0.38) | ALDH1A1LMNABLMCYP3A4NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2084519-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | Los Alamos National Security, LLC (US) | 2009-08-05 | — | — | EP | claimed |
| WO-2008127291-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2008-10-23 | — | — | WO | claimed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | claimed |
| US-10877035-B2 | Advanced drug development and manufacturing | ICAGEN, LLC (US) | 2020-12-29 | — | — | US | disclosed |
| US-20150240226-A1 | NUCLEIC ACIDS AND PROTEINS AND METHODS FOR MAKING AND USING THEM | BP CORP NORTH AMERICA INC (US) | 2015-08-27 | — | — | US | disclosed |
| EP-2511844-B1 | X-ray microscope | XRPRO SCIENCES INC (US) | 2015-08-12 | — | — | EP | disclosed |
| US-8962800-B2 | Nucleic acids and proteins and methods for making and using them | BP CORPORATION NORTH AMERICA INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20120266329-A1 | Nucleic Acids and Proteins and Methods for Making and Using Them | BP CORPORATION NORTH AMERICA INC. (US) | 2012-10-18 | — | — | US | disclosed |
| EP-2511844-A2 | Advanced drug development and manufacturing | Los Alamos National Security, LLC (US) | 2012-10-17 | — | — | EP | disclosed |
| EP-2084519-B1 | X-RAY FLUORESCENCE ANALYSIS METHOD | LOS ALAMOS NAT SECURITY LLC (US) | 2012-08-01 | — | — | EP | disclosed |
| US-8119385-B2 | Nucleic acids and proteins and methods for making and using them | BP CORPORATION NORTH AMERICA INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110296543-A1 | NUCLEIC ACIDS AND PROTEINS AND METHODS FOR MAKING AND USING THEM | THE UNIVERSITY OF CALIFORNIA (US) | 2011-12-01 | — | — | US | disclosed |
| US-20100011456-A1 | Nucleic Acids and Proteins and Methods for Making and Using Them | VERENIUM CORPORATION (US) | 2010-01-14 | — | — | US | disclosed |
| EP-2084519-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | Los Alamos National Security, LLC (US) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008127291-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150240226-A1 | NUCLEIC ACIDS AND PROTEINS AND METHODS FOR MAKING AND USING THEM | POLN, POLM, POLI | ALDH1A1 2292/4885GABBR2 4096/4885GABBR1 4085/4885 |
| US-20120266329-A1 | Nucleic Acids and Proteins and Methods for Making and Using Them | POLN, POLM, POLI | ALDH1A1 2292/4885GABBR2 4096/4885GABBR1 4085/4885 |
| US-20100011456-A1 | Nucleic Acids and Proteins and Methods for Making and Using Them | POLN, POLM, POLI | ALDH1A1 2292/4885GABBR2 4096/4885GABBR1 4085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.